NOD2 and metabolic dysfunction-associated steatohepatitis: investigated whether NOD2-deficient mice are sensitive to NASH-associated liver cancer and showed that upon the treatment with DMBA and consumption of HFD, NOD2-deficient mice gained more weight and bore more HCC tumors than NOD2-intact mice (45).